PMID- 31735842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200928
IS  - 2411-5150 (Electronic)
IS  - 2411-5150 (Linking)
VI  - 3
IP  - 3
DP  - 2019 Aug 26
TI  - Treat and Extend Treatment Interval Patterns with Anti-VEGF Therapy in nAMD 
      Patients.
LID - 10.3390/vision3030041 [doi]
LID - 41
AB  - Treat and extend (T&E) is a standard treatment regimen for treating neovascular 
      age-related macular degeneration (nAMD) with anti-vascular endothelial growth 
      factors (anti-VEGFs), but the treatment intervals attained are not well 
      documented. This retrospective, non-comparative, non-randomised study of eyes 
      with nAMD classified treatment interval sequences in a T&E cohort in Australia 
      using Electronic Medical Records (EMR) data. We analysed data from 632 
      treatment-naive eyes from 555 patients injected with ranibizumab, aflibercept or 
      unlicensed bevacizumab between January 2012 and June 2016 (mean baseline age 
      78.0). Eyes were categorised into non-overlapping clusters of interval sequences 
      based on the first 12 months of follow-up. We identified 523 different treatment 
      interval sequences. The largest cluster of 197 (31.5%) eyes attained an 8-week 
      treatment interval before dropping to a shorter frequency, followed by 168 
      (26.8%) eyes that did not reach or attained a single 8-week interval at the end 
      of the study period. A total of 65 (10.4%) and 83 (13.3%) eyes reached and 
      sustained (>/=2 consecutive injection intervals of the same length) an 8 and 12 
      weekly interval, respectively. This study demonstrates highly individualised 
      treatment patterns in the first year of anti-VEGF therapy in Australia using T&E 
      regimens, with the majority of patients requiring more frequent injections than 
      once every 8 weeks.
FAU - Skelly, Adrian
AU  - Skelly A
AD  - Novartis Pharma AG, 4002 Basel, Switzerland.
FAU - Bezlyak, Vladimir
AU  - Bezlyak V
AD  - Novartis Pharma AG, 4002 Basel, Switzerland.
FAU - Liew, Gerald
AU  - Liew G
AD  - Westmead Institute for Medical Research, University of Sydney, Westmead, NSW 
      2145, Australia.
FAU - Kap, Elisabeth
AU  - Kap E
AD  - IQVIA Commercial GmbH & Co. OHG, 60549 Frankfurt, Germany.
FAU - Sagkriotis, Alexandros
AU  - Sagkriotis A
AD  - Novartis Pharma AG, 4002 Basel, Switzerland.
LA  - eng
PT  - Journal Article
DEP - 20190826
PL  - Switzerland
TA  - Vision (Basel)
JT  - Vision (Basel, Switzerland)
JID - 101733282
PMC - PMC6802800
OTO - NOTNLM
OT  - aflibercept
OT  - age-related macular degeneration
OT  - anti-VEGF
OT  - nAMD
OT  - ranibizumab
OT  - treat and extend
OT  - unlicensed bevacizumab
COIS- Adrian Skelly, Vladimir Bezlyak and Alexandros Sagkriotis are employees of 
      Novartis Pharma AG, Basel, Switzerland. Elisabeth Kap is an employee of IQVIA 
      Commercial GmbH, Frankfurt, Germany. Gerald Liew has received an educational 
      fellowship grant partially funded by Novartis Pharma AG over 7 years ago.
EDAT- 2019/11/19 06:00
MHDA- 2019/11/19 06:01
PMCR- 2019/08/26
CRDT- 2019/11/19 06:00
PHST- 2019/07/04 00:00 [received]
PHST- 2019/08/07 00:00 [revised]
PHST- 2019/08/21 00:00 [accepted]
PHST- 2019/11/19 06:00 [entrez]
PHST- 2019/11/19 06:00 [pubmed]
PHST- 2019/11/19 06:01 [medline]
PHST- 2019/08/26 00:00 [pmc-release]
AID - vision3030041 [pii]
AID - vision-03-00041 [pii]
AID - 10.3390/vision3030041 [doi]
PST - epublish
SO  - Vision (Basel). 2019 Aug 26;3(3):41. doi: 10.3390/vision3030041.